PubRank

Marc H Dahlke

Author PubWeight™ 23.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006 1.64
2 Intestinal ischemia: current treatment concepts. Langenbecks Arch Surg 2010 1.60
3 High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol 2010 1.42
4 Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007 1.30
5 Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007 1.29
6 Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010 1.07
7 Mesenchymal stem cells can affect solid organ allograft survival. Transplantation 2009 1.01
8 Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). J Transl Med 2011 0.97
9 Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl 2009 0.97
10 No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2006 0.94
11 Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials. Transplantation 2013 0.93
12 Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011 0.93
13 Therapeutic potential of bone marrow stem cells for liver diseases. Curr Stem Cell Res Ther 2006 0.92
14 Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med 2013 0.89
15 Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation. Trials 2012 0.83
16 Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats. Exp Hematol 2007 0.81
17 Rationale and prospects of mesenchymal stem cell therapy for liver transplantation. Curr Opin Organ Transplant 2014 0.81
18 Caveats of mesenchymal stem cell therapy in solid organ transplantation. Transpl Int 2014 0.79
19 Intraportal injection of porcine multipotent mesenchymal stromal cells augments liver regeneration after portal vein embolization. In Vivo 2009 0.79
20 Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2010 0.79
21 Double deficiency for RORγt and T-bet drives Th2-mediated allograft rejection in mice. J Immunol 2013 0.77
22 Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice. Exp Hematol 2008 0.77
23 Maximising impact of small cohort studies. Transpl Int 2013 0.75
24 Making hepatocytes from stem cells: where are we? Liver Transpl 2003 0.75
25 Manipulation of CD45 antigen in transplantation tolerance. Curr Mol Med 2002 0.75
26 Mesenchymal stromal cells for immunoregulation after liver transplantation: the scene in 2016. Curr Opin Organ Transplant 2016 0.75